{"id":"W4306711477","doi":"10.1016/j.ejca.2022.10.003","title":"Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Aptitude Health; Oncolytics Biotech; Eisai; Seagen; Bayer HealthCare; G1 Therapeutics; Silverback Therapeutics; Puma Biotechnology; BioTheranostics; Ipsen; OncoSec Medical; Syndax Pharmaceuticals; Mersana Therapeutics; Queen Mary University of London; Clovis Oncology; Mylan; MacroGenics; Celldex Therapeutics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Taiho Pharmaceutical; Ipsen Biopharmaceuticals; F. Hoffmann-La Roche; Radius Health; Amgen; Ariad Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Servier; Gilead Sciences; Baxalta; Foundation Medicine; Genomic Health; AbbVie; Revolution Medicines; Exelixis; Sanofi; Incyte; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Quality of life (healthcare); Breast cancer; Nausea; Population; Vinorelbine; Gemcitabine; Oncology; Eribulin; Metastatic breast cancer; Capecitabine; Cancer; Chemotherapy; Physical therapy; Colorectal cancer; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004418644,0.0002217534,0.00129956,0.0003010847,0.00006620646,0.000007619773,0.000341205,0.00001558576,0.000855952],"category_scores_gemma":[0.0001848457,0.0001628701,0.0002505321,0.0008511509,0.0001985433,0.000124651,0.00004042706,0.0007873951,3.073593e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001337297,"about_ca_system_score_gemma":0.001851707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001602875,"about_ca_topic_score_gemma":0.0005668586,"domain_scores_codex":[0.9937803,0.002376287,0.002164791,0.0002094341,0.001160597,0.0003085677],"domain_scores_gemma":[0.9964573,0.0002734564,0.002538375,0.0002876467,0.0002981207,0.0001451076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7728052,0.001159857,0.0008391177,0.00013841,0.000743731,0.00009506236,0.01590299,0.002586125,0.0008469902,0.00007353487,0.000315041,0.2044939],"study_design_scores_gemma":[0.9161226,0.01223365,0.04986624,0.0008104125,0.0001992926,0.0001104276,0.01191916,0.00006084883,0.0006769149,0.0001415631,0.007539985,0.0003189022],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768846,0.008865759,0.0001820287,0.01145946,0.0008557728,0.001013085,0.000512933,0.000007480889,0.000218852],"genre_scores_gemma":[0.9978086,0.0009216748,0.0001861817,0.0007649444,0.0001923155,0.00003141282,0.00000406686,0.00004639245,0.00004441279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.204175,"threshold_uncertainty_score":0.9372074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05695953814471598,"score_gpt":0.39383531743827,"score_spread":0.336875779293554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}